Anthrax Vaccine Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Anthrax Vaccine Market Trends and Insights

Government Biodefense Stockpiling Budgets Increasing Post-COVID

National budgets reclassified anthrax countermeasures as core security assets. The U.S. Strategic National Stockpile expanded multi-year contracts, including a USD 250 million modification covering CYFENDUS, highlighting lessons from pandemic supply bottlenecks. Canada’s Health Emergency Readiness Canada initiative adds regional alignment with domestic manufacturing capacity^{[2]Source: U.S. Department of Health and Human Services, “PHEMCE Multiyear Budget: Fiscal Years 2023–2027,” aspr.hhs.gov}. Defense Threat Reduction Agency grants of USD 26.3 million sustain R&D pipelines, ensuring that the anthrax vaccine market remains integrated into broader chemical–biological defense funding.

Mandatory Vaccination Programs for Military & High-Risk Lab Personnel

Compulsory protocols broaden beyond troops to laboratory and emergency response staff, reinforcing the anthrax vaccine market in established buying centers. The CDC’s 2023 guideline update enlarges the eligible workforce, while an FDA-approved five-dose schedule improves adherence logistics. NATO interoperability standards likewise push adoption across allied forces.

Regulatory Approvals of Next-Generation Vaccines (e.g., CYFENDUS)

The FDA’s 2023 clearance of CYFENDUS validated fast-acting adjuvanted formulations with a two-dose post-exposure protocol. South Korea’s 2025 approval of recombinant GC-1109 underscores global regulatory receptivity to synthetic biology platforms. BARDA’s Target Product Profiles now prioritize single-dose efficacy, incentivizing R&D toward simplified regimens.

Rising Geopolitical Bioterrorism Threat Perception Globally

Regional security briefs cite potential weaponization of Bacillus anthracis, prompting increased procurement. South Korea’s readiness plans against North Korean capabilities and U.S. intelligence on dual-use biotech in China illustrate the strategic value placed on rapid-response vaccines.

Adverse-Event Profile & Litigation Risk Limits Civilian Uptake

Injection-site reactions and past legal disputes dampen broad-based demand. Civilian insurers seldom reimburse preventive doses, and no pediatric indication exists, narrowing the anthrax vaccine market beyond government channels.

Dependence on a Single Dominant Supplier Creates Supply Risk

Emergent BioSolutions’ facility closures in 2024 exposed fragility in an almost single-supplier ecosystem, prompting governments to hedge through recombinant and contract-manufacture alternatives

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Vaccine Type: Cell-Free Dominance Faces Adjuvanted Challenge

Cell-free formulations commanded 48.12% anthrax vaccine market share in 2025 as longstanding familiarity drove procurement. Adjuvanted AV7909, led by CYFENDUS, grows at 8.01% CAGR on faster seroconversion that meets emergency timelines. Manufacturing strategies pivot toward recombinant antigens, evidenced by GC-1109’s licensure, easing biosafety constraints inherent in culture-based production. Patent filings for thermostable spray-dried doses aim to remove cold-chain costs and widen reach in low-resource markets.

A future pipeline that includes mRNA and viral-vector concepts remains preclinical but could disrupt the anthrax vaccine industry if single-dose efficacy targets are met. Cross-sector lessons from COVID-19 have validated adjuvant dose-sparing frameworks, likely accelerating platform diversification.

By End User: Military Dominance Yields to Civilian Growth

Military & Defense held 55.02% of the anthrax vaccine market size in 2025, anchored by locked-in contracts and deployment protocols. Civilian agencies expand at 8.32% CAGR, propelled by CDC guidance encompassing lab workers and first responders. Veterinary and One Health programs grow where endemic livestock outbreaks occur, linking animal health budgets to human countermeasure funding.

International collaborations, such as India’s BioThrax partnership with Biological E., bring supply closer to regional civilian buyers, easing import reliance and raising baseline demand across South Asia investors.emergentbiosolutions.com. Research institutions also raise call-off volumes to satisfy biosafety clearances for anthrax-related experimentation.

By Application: Pre-Exposure Protocols Drive Current Demand

Pre-Exposure vaccination secured 59.63% of the anthrax vaccine market size in 2025 on embedded military schedules. Post-Exposure demand accelerates at 8.78% CAGR as CYFENDUS enables two-dose prophylaxis, meeting BARDA’s rapid-response benchmarks. Integrated stockpile strategies purchase both antibiotics and vaccines, creating bundled contracts that reward suppliers with diversified portfolios.

Therapeutic applications stay exploratory. However, synthetic biology efforts hint at dual-action constructs that might blur the line between prophylaxis and treatment, expanding future addressable volumes for the anthrax vaccine market.

By Distribution Channel: Direct Procurement Maintains Control

Direct Government Procurement accounted for 69.10% market share in 2025 as security protocols dictate centralized buying. Allied nations increasingly arrange direct-order agreements under mutual-defense frameworks, giving Direct Order Suppliers a 9.12% CAGR outlook. Commercial pharmacy distribution remains negligible except under emergency use authorizations, reflecting controlled-substance status of biodefense countermeasures.

Facility realignments have inspired interest in multi-site contract manufacturing; Scorpius BioManufacturing’s plan to produce Anthim antitoxin in Kansas signals emerging redundancy in the supply chain.

Geography Analysis

North America retained 58.05% anthrax vaccine market share in 2025, supported by the Strategic National Stockpile’s rolling replenishments and consistent FDA approvals. A USD 2 billion domestic manufacturing drive under the BioMaP-Consortium strengthens regional self-reliance, while Canada’s HERC program aligns cross-border capacity.

Asia-Pacific posts the fastest CAGR at 9.35% to 2031. South Korea’s GC-1109 breakthrough and India’s BioThrax approval embed local production, diminishing sole dependence on U.S. supply and amplifying regional orders. Thailand’s 2025 anthrax outbreak response highlighted the urgency for wider livestock and human vaccine availability, prompting ASEAN regulators to discuss harmonized fast-track pathways.

Europe sustains moderate growth as the EU’s Health Technology Assessment Regulation targets synchronized member-state decisions on critical vaccines. Recent African outbreaks drive donor-funded procurements, although constrained budgets limit immediate volume. Latin American interest rises slowly, awaiting structured financing mechanisms that could tap into regional development banks.

Regulatory Landscape

Anthrax vaccines are regulated as biologics, with U.S. oversight centered on the FDA Center for Biologics Evaluation and Research (CBER) under the Public Health Service Act (Section 351(a)) and cGMP requirements. In the United States, BioThrax and CYFENDUS form the core of the licensed anthrax vaccine portfolio for preparedness use, and CYFENDUS was approved under 21 CFR 601 Subpart H (Animal Rule), which supports the pathway for next-generation countermeasures that depend on controlled manufacturing and post-licensure commitments.

Procurement-linked regulatory touchpoints also influence deployability, including lot release, labeling, and storage requirements for stockpile use. A notable milestone was the FDA approval of a supplemental BLA for CYFENDUS in November 2025 to update storage, handling, and labeling, which is designed to support broader field logistics for the Strategic National Stockpile and other government-managed inventories coordinated through the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).

Value Chain Analysis

The value chain is anchored by government-driven demand signals that translate into multi-year R&D, procurement, and replenishment cycles. In the United States, procurement flows are dominated by the Department of Defense (for pre-exposure readiness) and HHS/ASPR BARDA (for stockpile building), using long-term IDIQ structures such as the JPEO-CBRND contract awarded in January 2024 for BioThrax supply through September 2033, complemented by BARDA options and modifications for CYFENDUS deliveries.

Upstream suppliers rely on specialized biologics inputs (antigens, adjuvants, sterile fill-finish components) and controlled production environments. Midstream bottlenecks include validation, cGMP compliance, and government lot release timelines, while downstream activity is primarily direct government procurement into national stockpiles and military medical logistics channels, with limited commercial pathways. Diversification is emerging as countries such as South Korea add domestic recombinant production capacity via GC Biopharma's Barythrax (GC-1109), reducing reliance on a single external supplier for national stockpile needs.

Market Opportunities and Future Outlook

A primary opportunity is supplier and platform diversification tied to preparedness mandates and stockpile sustainment, where procurement actions reflect active budgeted demand rather than episodic buying. The U.S. market continues to be refreshed through repeat ordering mechanisms under long-duration contracts, including the DoD IDIQ framework for BioThrax extending to 2033, along with BARDA contracting actions that have funded CYFENDUS deliveries into the stockpile system. This procurement environment favors vendors that can meet cGMP, lot release, and surge delivery requirements.

Regional manufacturing sovereignty, particularly in Asia-Pacific, is progressing as regulatory approvals and facility-backed programs translate into domestic supply capability. South Korea's approval of GC Biopharma's recombinant Barythrax (GC-1109) supports a local production base for national stockpiling (with reported output range of 150,000 to 300,000 doses), creating room for additional recombinant entrants, contract manufacturing participation, and adjacent enabling services (fill-finish, cold-chain optimization, and validated storage and handling systems) that meet government procurement specifications.